ALX Oncology Holdings Inc – Jahresabschlüsse (NASDAQ:ALXO) | MetaTrader

Vollständige Grafik anzeigen

Nachrichten

ALX Oncology beruft Jeff Knight zum Chief Development Officer

Wells Fargo startet Coverage für ALX Oncology mit ’Overweight’-Rating

ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA

CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data

IBRX Stock Jumps on Progress in NK Cell Therapy Production

JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study

RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study

RLMD Stock Surges 42% in a Week: Here's What You Should Know

GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma

EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y

Roche's Giredestrant Misses Key Goal in First-Line Breast Cancer Study

LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?